NEW YORK (GenomeWeb News) – Researchers from the University of Minnesota and biotech firm Celladon have developed a high-throughput screening method that may help speed the development of drugs to treat heart failure, the university said this week.

Celladon, based in La Jolla, Calif., recently licensed exclusive rights to the technology from UM, and continues to work with researchers at the university to explore how the assay might be applied to other diseases, and to possibly conduct a large-scale screening campaign for drug candidates, officials said this week.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.